DSIP (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

DSIP (Delta Sleep-Inducing Peptide) is a small naturally occurring nonapeptide studied for its influence on slow-wave sleep and on the stress-response axis. The numbers below are assembled purely for laboratory and educational reference — they describe how the compound has been prepared and dosed in published research, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 6.0 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL). At that concentration, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 500 mcg of material, so each single unit on the barrel corresponds to 50 mcg — fine enough resolution to measure the low microgram doses used in the sleep literature.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow ramp commonly modelled in the chronic-insomnia trials, where evening amounts were stepped up across the first several weeks and then held at a steady maintenance level once a response was established.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 6.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet, which helps avoid foaming.
3. Swirl or roll gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (5 mg/mL) and the reconstitution date.
5. Refrigerate upright between uses and draw subsequent volumes with a fresh sterile syringe each time.

Evening-Loaded Schedule (Reference Variant)

Some study designs front-load a slightly higher evening dose for a defined window rather than escalating slowly. This variant holds a fixed nightly amount near the top of the research band from the outset, which is reflected in a flat maintenance table rather than a stepped ramp.

Supplies Needed

• DSIP vials (30 mg): a single 30 mg vial covers a full 8–12 week daily run at 5 mg/mL, since the per-dose volumes are very small.
• Insulin syringes (U-100, 0.3–0.5 mL): ~56 for an 8-week daily schedule; ~84 for 12 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle supplies the 6 mL needed to reconstitute one vial with margin to spare.
• Alcohol swabs: ~112 for 8 weeks or ~168 for 12 weeks (vial stopper plus site, per draw).

Protocol Overview

• Research goal: model slow-wave sleep promotion and HPA-axis (stress-response) modulation.
• Schedule: once-daily subcutaneous administration, typically in the evening, in the published model.
• Dose band: 100–300 mcg daily.
• Fill: 30 mg lyophilized, reconstituted to 5 mg/mL with 6 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 100 mcg step and raise gradually across the first few weeks where a stepped model is used.
• Keep administration on a fixed evening cadence; timing is emphasised more than magnitude in the sleep literature.
• Hold the maintenance level once a stable response is observed rather than continuing to escalate.
• Because doses are very small, draw carefully and verify the unit mark on the barrel before each measurement.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and protect from light. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times over a long run.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact across many small draws.
• Measure the low-microgram volumes slowly and confirm the unit count before withdrawing the needle.
• Document each draw — date, volume, remaining material — for reproducibility.

How DSIP Works

DSIP is a short nonapeptide that behaves as a neuromodulator of the sleep–wake cycle and the stress response. In EEG studies its administration is associated with an increase in delta-wave (slow-wave), non-REM sleep, pointing to a role in initiating and sustaining deep sleep. The peptide readily crosses the blood–brain barrier to act centrally, where it appears to favour inhibitory neuronal activity and to engage sleep-regulating regions of the brain. Separately, DSIP has been reported to blunt ACTH and corticosterone release under stress, implying an action on the hypothalamic–pituitary–adrenal axis that links its sleep and stress effects.

Reported Benefits & Side Effects

Benefits observed in research

• Increased slow-wave (delta) sleep duration and reports of improved overall sleep quality.
• Potential normalisation of disrupted sleep patterns in chronic-insomnia study populations.
• Signals of stress reduction and mood support attributed to HPA-axis modulation.
• Additional exploratory work in chronic-pain and withdrawal-syndrome contexts.

Side effects reported

• An unusually clean safety profile — animal studies found no lethal dose even at very high amounts.
• Human reports note only mild, transient effects such as occasional headache or nausea.
• Occasional mild injection-site reactions (redness or itching).

Supporting Lifestyle Factors (Research Context)

• Consistent sleep–wake timing and a dark, low-stimulation evening environment as standard study controls.
• Limited late-day caffeine and screen exposure in the modelled protocols.
• Stress-management routines that complement the peptide's HPA-axis activity.

Injection Technique (Reference Only)

• Prepare the vial and site with alcohol swabs and let them dry.
• Insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Keep the small dose volume in a single injection — there is no need to split at these microgram amounts.
• Rotate sites systematically and dispose of sharps in an approved container.

References

Related Protocols